TABLE 1.
Baseline characteristics
| Patient characteristics | Total Sample, N = 116 | Subgroup Age | Subgroup Compliance | ||
|---|---|---|---|---|---|
| <70 years, n = 78 | ≥70 years, n = 38 | ≥3 Questionnaires, n = 90 | <3 Questionnaires, n = 26 | ||
| Demographics | |||||
| Sex, n (%) | |||||
| Male | 70 (60.3) | 47 (60.3) | 23 (60.5) | 58 (64.4) | 12 (46.1) |
| Female | 46 (39.7) | 31 (39.7) | 15 (39.5) | 32 (35.6) | 14 (53.9) |
| Age | |||||
| Mean in years (SD) | 66.2 (8.25) | 62.0 (6.27)a | 74.8 (3.96)a | 66.3 (7.84) | 65.7 (9.72) |
| Range in years | 41–83 | 41–69 | 70–83 | 41–81 | 42–83 |
| Medical | |||||
| Time since diagnosis | |||||
| Mean in years (SD) | 6.5 (5.11) | 6.2 (5.29) | 7.2 (4.69) | 5.8 (4.53)a | 8.8 (6.28)a |
| Range in years | 1.0–25.2 | 1.0–25.2 | 1.0–18.5 | 1.0–23.5 | 1.2–25.2 |
| Use of advanced therapies | |||||
| Any, n (%) | 18 (15.5) | 12 (15.4) | 6 (15.8) | 12 (13.3) | 6 (23.1) |
| Apomorfine, n | 4 | 3 | 1 | 3 | 1 |
| DBS, n | 2 | 2 | 0 | 2 | 0 |
| LCIS, n | 12 | 7 | 5 | 7 | 5 |
a
Significant (P < 0.05) difference between subgroups.
SD, standard deviation; DBS, deep brain stimulation; LCIG, levodopa‐carbidopa intestinal gel.